Phase II trial of 177lutetium radiolabeled anti-PSMA antibody J591 (177Lu-J591) for metastatic castrate-resistant prostate cancer (metCRPC): Survival update and expansion cohort with biomarkers.
Scott T. Tagawa
No relevant relationships to disclose
Naveed Hassan Akhtar
No relevant relationships to disclose
Joseph Osborne
No relevant relationships to disclose
Paul J. Christos
No relevant relationships to disclose
Shankar Vallabhajosula
No relevant relationships to disclose
Stanley J. Goldsmith
No relevant relationships to disclose
Renee Kahn
No relevant relationships to disclose
Caryn Ecker
No relevant relationships to disclose
Himisha Beltran
No relevant relationships to disclose
Michael J. Morris
No relevant relationships to disclose
Matthew I. Milowsky
No relevant relationships to disclose
Neil Harrison Bander
Consultant or Advisory Role - BZL Biologics
Stock Ownership - BZL Biologics
David M. Nanus
No relevant relationships to disclose